Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice - PubMed (original) (raw)

Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice

A Fredriksson et al. J Neural Transm (Vienna). 2001.

Abstract

The antiparkinsonian effects of the uncompetitive NMDA antagonists, memantine, amantadine and MK-801, in combination with an acute subthreshold dose of L-Dopa (5 mg/kg) in drug-naive MPTP-treated mice or a suprathreshold dose (20 mg/kg) in L-Dopa tolerant MPTP-treated mice were investigated. In the former case, memantine (locomotion: 3 mg/kg; rearing: 1 mg/kg) and amantadine (locomotion and rearing: 10 mg/kg) injected 60 min before the subthreshold dose of L-Dopa (5 mg/kg), each induced an antiparkinsonian action in hypokinesic MPTP-treated mice that consisted of dose-specific, as opposed to dose-related, elevations of locomotion and rearing behaviour. At the same time, higher doses of memantine reduced further the rearing (10 and 30 mg/kg) and locomotor (30mg/kg) behaviour of the MPTP-treated mice. MK-801 plus L-Dopa elevated locomotion (0.1 mg/kg) but reduced rearing at the 0.3 mg/kg dose. In control, saline-treated mice, memantine (3, 10 and 30 mg/kg) and MK-801 (0.1 and 0.3 mg/kg) increased locomotor behaviour but decreased rearing behaviour, while amantadine produced no effects. Memantine increased locomotor (1 and 3 mg/kg, s.c.; 1 mg/kg dose restored activity) and rearing (0.3 and 3 mg/kg) activity in the L-Dopa tolerant MPTP-treated mice, whereas amantadine (3 and 10 mg/kg) restored both locomotor (30 mg/kg significantly increased locomotion but did not restore the activity level) and rearing (3 mg/kg only) activity. MK-801 (0.1 and 0.3 mg/kg, s.c.) also increased significantly locomotor activity of L-Dopa-tolerant MPTP mice although the antikinetic action was not reversed, thereby precluding a restorative effect of the compound. These results, demonstrating both a synergistic and a restorative effect of the NMDA antagonists in coadministration with L-Dopa, demonstrate a putative antiparkinson action by these compounds in a functional animal model that incorporates the "wearing-off" complications of L-Dopa administration in the disorder.

PubMed Disclaimer

Similar articles

• Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
  Fredriksson A, Archer T. Fredriksson A, et al. Amino Acids. 2002;23(1-3):111-32. doi: 10.1007/s00726-001-0117-3. Amino Acids. 2002. PMID: 12373526
• Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists.
  Fredriksson A, Palomo T, Chase T, Archer T. Fredriksson A, et al. J Neural Transm (Vienna). 1999;106(3-4):283-300. doi: 10.1007/s007020050158. J Neural Transm (Vienna). 1999. PMID: 10392537
• Effects of co-administration of anticonvulsant and putative anticonvulsive agents and sub/suprathreshold doses of L-dopa upon motor behaviour of MPTP-treated mice.
  Fredriksson A, Palomo T, Archer T. Fredriksson A, et al. J Neural Transm (Vienna). 1999;106(9-10):889-909. doi: 10.1007/s007020050209. J Neural Transm (Vienna). 1999. PMID: 10599871
• Effect of postnatal iron administration on MPTP-induced behavioral deficits and neurotoxicity: behavioral enhancement by L-Dopa-MK-801 co-administration.
  Fredriksson A, Archer T. Fredriksson A, et al. Behav Brain Res. 2003 Feb 17;139(1-2):31-46. doi: 10.1016/s0166-4328(02)00035-9. Behav Brain Res. 2003. PMID: 12642174
• Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies.
  Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G. Danysz W, et al. Neurosci Biobehav Rev. 1997 Jul;21(4):455-68. doi: 10.1016/s0149-7634(96)00037-1. Neurosci Biobehav Rev. 1997. PMID: 9195603 Review.

Cited by

• NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment.
  North WG, Gao G, Jensen A, Memoli VA, Du J. North WG, et al. Clin Pharmacol. 2010;2:31-40. doi: 10.2147/CPAA.S6262. Epub 2010 Apr 1. Clin Pharmacol. 2010. PMID: 22291485 Free PMC article.
• Pharmacodynamics of memantine: an update.
  Rammes G, Danysz W, Parsons CG. Rammes G, et al. Curr Neuropharmacol. 2008 Mar;6(1):55-78. doi: 10.2174/157015908783769671. Curr Neuropharmacol. 2008. PMID: 19305788 Free PMC article.
• Awake 18F-FDG PET Imaging of Memantine-Induced Brain Activation and Test-Retest in Freely Running Mice.
  Miranda A, Glorie D, Bertoglio D, Vleugels J, De Bruyne G, Stroobants S, Staelens S, Verhaeghe J. Miranda A, et al. J Nucl Med. 2019 Jun;60(6):844-850. doi: 10.2967/jnumed.118.218669. Epub 2018 Nov 15. J Nucl Med. 2019. PMID: 30442754 Free PMC article.
• MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
  Paquette MA, Anderson AM, Lewis JR, Meshul CK, Johnson SW, Paul Berger S. Paquette MA, et al. Neuropharmacology. 2010 Jun;58(7):1002-8. doi: 10.1016/j.neuropharm.2010.01.003. Epub 2010 Jan 14. Neuropharmacology. 2010. PMID: 20079362 Free PMC article.
• Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity.
  Fredriksson A, Schröder N, Archer T. Fredriksson A, et al. Neurotox Res. 2003;5(1-2):53-76. doi: 10.1007/BF03033373. Neurotox Res. 2003. PMID: 14628856 No abstract available.

References

1. 1. J Neural Transm Gen Sect. 1994;97(3):197-209 - PubMed
2. 1. J Neural Transm Park Dis Dement Sect. 1994;7(2):123-32 - PubMed
3. 1. Pharmacol Toxicol. 1990 Oct;67(4):295-301 - PubMed
4. 1. Eur J Neurosci. 1996 Mar;8(3):446-54 - PubMed
5. 1. Eur J Pharmacol. 1986 Oct 7;129(3):339-45 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database